Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Gary M Strauss, James E Herndon 2nd, Michael A Maddaus, David W Johnstone, Elizabeth A Johnson, David H Harpole, Heidi H Gillenwater, Dorothy M Watson, David J Sugarbaker, Richard L Schilsky, Everett E Vokes, Mark R Green, Gary M Strauss, James E Herndon 2nd, Michael A Maddaus, David W Johnstone, Elizabeth A Johnson, David H Harpole, Heidi H Gillenwater, Dorothy M Watson, David J Sugarbaker, Richard L Schilsky, Everett E Vokes, Mark R Green

Abstract

Purpose: Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear. This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC.

Patients and methods: Within 4 to 8 weeks of resection, patients were randomly assigned to adjuvant chemotherapy or observation. Eligible patients had pathologically confirmed T2N0 NSCLC and had undergone lobectomy or pneumonectomy. Chemotherapy consisted of paclitaxel 200 mg/m(2) intravenously over 3 hours and carboplatin at an area under the curve dose of 6 mg/mL per minute intravenously over 45 to 60 minutes every 3 weeks for four cycles. The primary end point was overall survival.

Results: Three hundred-forty-four patients were randomly assigned. Median follow-up was 74 months. Groups were well-balanced with regard to demographics, histology, and extent of surgery. Grades 3 to 4 neutropenia were the predominant toxicity; there were no treatment-related deaths. Survival was not significantly different (hazard ratio [HR], 0.83; CI, 0.64 to 1.08; P = .12). However, exploratory analysis demonstrated a significant survival difference in favor of adjuvant chemotherapy for patients who had tumors > or = 4 cm in diameter (HR, 0.69; CI, 0.48 to 0.99; P = .043).

Conclusion: Because a significant survival advantage was not observed across the entire cohort, adjuvant chemotherapy should not be considered standard care in stage IB NSCLC. Given the magnitude of observed survival differences, CALGB 9633 was underpowered to detect small but clinically meaningful improvements. A statistically significant survival advantage for patients who had tumors > or = 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors.

Figures

Fig A1.
Fig A1.
Survival curve at the time of accrual termination.
Fig 1.
Fig 1.
Consort diagram.
Fig 2.
Fig 2.
Kaplan-Meier estimates of survival among patients who received adjuvant paclitaxel and carboplatin and those who underwent observation alone. (A) Overall survival, all patients; (B) disease-free survival, all patients; (C) tumor size ≥ 4 cm in diameter; and (D) tumor size

References

    1. Le Chevalier T, et al: Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) versus no CT in 1867 patients with resected non–small-cell lung cancer. Proc Am Soc Clin Oncol 22:2, 2003. (abstr 6)
    1. Arriagada R, Bergman B, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer: The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group. N Engl J Med 350:351-360, 2004
    1. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004
    1. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
    1. Strauss GM, Herndon JE, Maddaus MA, et al: Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non–small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22:621s, 2004. (suppl; abstr 7019)
    1. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non–small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomized controlled trial. Lancet Oncology 7:719-727, 2006
    1. Strauss GM, Rathore R: Lung cancer, in Crapo JD, Glassroth J, Karlinsky JB, et al (eds): Baum's Textbook of Pulmonary Diseases. Philadelphia, PA, Lippincott Williams & Wilkins, 2004, pp 787-857
    1. Mountain CE: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
    1. Natale R: Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non–small-cell lung cancer. Semin Oncol 23:51-54, 1996. (suppl 16)
    1. Langer C, Leighton J, Comis R, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non–small-cell lung cancer: A phase II toxicity, response and survival analysis. J Clin Oncol 13:1860-1870, 1995
    1. Kelly K, Crowley J, Bunn P Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
    1. Schiller JH, Harrington A, Belani C, et al: Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 346:92-98, 2002
    1. Lilenbaum RC, Herndon JE Jr, List MA, et al: Single-agent versus combination chemotherapy in advanced non–small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 23:190-196, 2005
    1. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non–small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004
    1. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007
    1. Scagliotti G, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non–small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
    1. Pignon J, Tribodet H, Scagliotti J, et al: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 24:366s, 2006. (suppl; abstr 7008)
    1. Lan GGK, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
    1. Pampallona S, Tsiatis A: Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plan Inference 42:19-35, 1994
    1. O’Brien P, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
    1. Lopez-Encuentra A, Duque-Medina J, Rami-Porta R, et al: Is 3 cm a prognostic threshold in pathologic stage I non–small-cell lung cancer? A multicenter study of 1,020 patients. Chest 121:1515-1520, 2002
    1. Mery CM, Pappas AN, Burt BM, et al: Diameter of non–small-cell lung cancer correlates with long-term survival: Implications for T stage. Chest 128:3255-3260, 2005
    1. Rami-Porta R, Ball D, Crowley J, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593-602, 2007
    1. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
    1. Strauss G: Management of early-stage lung cancer: Past, present, and future adjuvant trials. Oncology 20:1651-1663, 2006
    1. Roselli M, Mariotti S, Ferroni P, et al: Postsurgical chemotherapy in stage IB non–small-cell lung cancer: Long-term survival in a randomized study. Int J Cancer 119:955-960, 2006
    1. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non–small-cell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007
    1. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non–small-cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 24:365s, 2006. (abstr 7007)
    1. Pignon JP, Massard C: Adjuvant therapy for early lung cancer: Reflections and perspectives. Oncology 20:1669-1673, 2006
    1. Dunant A, Pignon JP, Le Chevalier T, et al: Adjuvant chemotherapy for non–small-cell lung cancer: Contribution of the International Adjuvant Lung Trial. Clinical Cancer Res 11:5017s-5021s, 2005
    1. Langer CL: The role of adjuvant chemotherapy for elderly patients with non–small-cell lung cancer, in Corey J. Langer (eds): American Society of Clinical Oncology 2006 Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2006, pp 289-292

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren